Highlight therapeutics stock
WebFeb 4, 2024 · Highlight Therapeutics's latest funding round was a Series D for $27.17M on February 4, 2024. View all funding This profile has not been claimed. You're more than … WebMar 15, 2024 · April 12, 2024. TIME: 1015 -1215 PM CT. LOCATION: New Orleans Convention Center, Exhibit Halls B-C. Highlight will also present the following posters at AACR: PRESENTATION TITLE: Correlation of ...
Highlight therapeutics stock
Did you know?
WebApr 12, 2024 · This Insight Report provides a comprehensive analysis of the global Biologic Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and ... WebHighlight Therapeutics is a private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology. About Highlight Therapeutics Our lead drug candidate BO-112 is a best-in-class RNA-based therapy which has been demonstrated to initiate a … Highlight Therapeutics is a private, clinical-stage company dedicated to unlocking … Highlight believes BO-112 has a unique ability to modify tumor-intrinsic pathways … Highlight Therapeutics was founded in 2010 as a spin out of the Spanish … Highlight Therapeutics - Valencia. Parque Científico Universidad de Valencia Calle … Highlight Therapeutics announces follow-up results from Phase 2b study of BO-112 + … Antoni Ribas MD, PhD. Dr. Ribas is Professor of Medicine, Professor of … Highlight and Merck, known as MSD outside the U.S. and Canada, completed a … Advisory Board Science Science Dr Sonia Maciá Medical Director. Dr Sonia Maciá joined Highlight Therapeutics in …
WebJan 2, 2024 · Highlight Therapeutics is a private, clinical-stage company focused on immuno-oncology. Its lead drug candidate, BO-112, is a best-in-class RNA-based therapy that aims to “initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system.” WebApr 12, 2024 · According to analysts' consensus price target of $59.40, SpringWorks Therapeutics has a forecasted upside of 130.8% from its current price of $25.74. Amount of Analyst Coverage SpringWorks Therapeutics has only been the subject of 3 research reports in the past 90 days. See Top Rated MarketRank™ Stocks Here
WebHighlight Therapeutics has raised a total of €22.6M in funding over 3 rounds. Their latest funding was raised on Feb 4, 2024 from a Venture - Series Unknown round. Highlight … WebHighlight Therapeutics is a private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology. The company's lead drug candidate BO-112 is a best-in …
WebApr 17, 2024 · BO-112 is currently being investigated in a range of clinical trials as a monotherapy and in combination with checkpoint inhibitors. In addition to in-house research, Highlight Therapeutics has a number of external collaborators, including Merck & Co and UCLA. This information is provided by RNS, the news service of the London Stock Exchange.
WebApr 11, 2024 · According to analysts' consensus price target of $18.33, Foghorn Therapeutics has a forecasted upside of 195.7% from its current price of $6.20. Amount of Analyst Coverage Foghorn Therapeutics has only been the subject of 4 research reports in the past 90 days. See Top Rated MarketRank™ Stocks Here About Foghorn Therapeutics … how dangerous is indianaWebApr 12, 2024 · According to analysts' consensus price target of $3.00, Alaunos Therapeutics has a forecasted upside of 418.0% from its current price of $0.58. Amount of Analyst Coverage Alaunos Therapeutics has only been the subject of 1 research reports in the past 90 days. See Top Rated MarketRank™ Stocks Here About Alaunos Therapeutics … how dangerous is hypothyroidismWebApr 10, 2024 · The trading price of Seres Therapeutics Inc. (NASDAQ:MCRB) closed higher on Thursday, April 06, closing at $5.77, 2.85% higher than its previous close. In examining the 52-week price action we see that the stock hit a 52-week high of $9.49 and a 52-week low of $2.50. Over the past month, the stock has lost -2.86% in value. how dangerous is it to be a police officerWebApr 6, 2024 · CAMBRIDGE, Mass., April 06, 2024 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced upcoming oral presentations highlighting its transcription factor and … how many puffs in a cake barWebSep 30, 2024 · Highlight Therapeutics Study Details Tabular View No Results Posted Disclaimer How to Read a Study Record Study Description Go to Brief Summary: This is a phase 2, single arm, open label, adaptive design study to determine the preliminary anti-tumor activity and confirm the safety of IT BO-112 in combination with intravenous (IV) … how many puffs in a floventWebMar 15, 2024 · Highlight Therapeutics is a private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology. Our lead drug candidate BO-112 is a … how many puffs in advair 45/21WebApr 14, 2024 · Green Stock News for the New Green Economy. ... The cases highlight that VAL-083 may be a treatment option for recurrent RELA fusion-positive ependymoma and diffuse midline glioma refractory to other treatments. Safety and efficacy data will be updated at the poster presentation at the meeting. ... Kintara is developing two late-stage ... how many puffs in a disposable vape pen